FIG. 2.

HinfI digests of a 620-bp product from amplification of gyrA gene by PCR, resulting in three fragments. This experiment shows that there was no point mutation to abolish HinfI sites within gyrA region. Lanes: M, 123-bp ladder; 1 to 6, HinfI restriction digests of PCR product containing fully sensitive serovar Typhi (lanes 1 to 3), serovar Typhi resistant to ampicillin and cotrimoxazole (lane 4), and MDR serovar Typhi resistant to ampicillin, cotrimoxazole, tetracycline, streptomycin and with increased nalidixic acid and ciprofloxacin MICs (lanes 5 and 6).